

1 **An exploratory assessment of the impact of a novel risk assessment test on**
2 **breast cancer clinic waiting times and workflow: a discrete event**
3 **simulation model**

4 **Authors:** Alison F. Smith^{1,2}, Samuel N. Frempong^{1,2}, Nisha Sharma³, Richard
5 D. Neal¹, Louise Hick^{2,3}, Bethany Shinkins^{1,2}

6 **Affiliations**

- 7 1. Leeds Institute of Health Sciences (LIHS), University of Leeds, Leeds, UK.
8 2. NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC)
9 3. Leeds Teaching Hospitals NHS Trust (LTHT), Leeds, UK.

10 **Corresponding Author**

11 Dr Alison F Smith

12 Lecturer

13 Academic Unit of Health Economics,

14 Leeds Institute of Health Sciences,

15 University of Leeds,

16 Leeds,

17 LS2 9NL

18 Email: a.f.c.smith@leeds.ac.uk

19 **Abstract**

20 **Background:** Breast cancer clinics across the UK have long been struggling to cope with high
21 demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary
22 clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact
23 of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number
24 of clinic ‘overspill’ appointments generated.

25 **Methods:** A simulation model was built to reflect the annual flow of patients through a single UK
26 clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two
27 primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only
28 non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule
29 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for
30 delayed referral. A range of sensitivity analyses were conducted to explore the impact of key
31 uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly
32 clinics from the clinic schedule, were also explored.

33 **Results:** Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with
34 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, >98% of patients met
35 the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and
36 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one
37 weekly low-capacity clinic [N=10], and the results were robust to sensitivity analyses.

38 **Conclusions:** The findings from this early analysis indicate that risk prediction tools could have the
39 potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake
40 of heightened pressures resulting from the COVID-19 pandemic. Further research is required to
41 validate these findings with real world evidence; evaluate the broader clinical and economic impact of
42 the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test
43 and therefore not initially referred.

44

45 **Key words:** Breast Neoplasms; Secondary Care Centres; Computer Simulation

46 **Declarations**

47 **1. Ethics approval and consent to participate**

48 Not applicable (no human participants were involved in this research).

49 **2. Consent for publication**

50 Not applicable.

51 **3. Availability of data and materials**

52 The simulation model generated during the current study is available from the corresponding author
53 upon reasonable request.

54 **4. Competing interests**

55 AS, SF, RN and BS work at the University of Leeds. NS and LH work at the Leeds Teaching
56 Hospitals NHS Trust (LTHT). Both the University of Leeds and the LTHT have a royalty agreement
57 with PinPoint Data Science Ltd, meaning that those institutions are likely to benefit financially in the
58 event of the PinPoint test being commercially successful.

59 **5. Funding**

60 This work was funded by an Innovate UK Digital Health Technology Catalyst grant, as part of the
61 Industrial Strategy Challenge fund (project number: 105411). AS, SF, RN, LH and BS are supported
62 by the NIHR In-Vitro Diagnostics Evidence Co-operative (MIC). RN and BS are supported by the
63 CRUK CanTest Collaborative (grant number: C8640/A23385).

64 **6. Authors contributions**

65 AS conducted the data analysis for the model, developed and parameterised the model, analysed the
66 model results, and was the primary author of the manuscript. SF provided input on the model
67 development and parameterisation. NS provided clinical data for the model, supervised the data
68 analysis, and clinically validated the model. RN provided clinical oversight throughout the
69 development and analysis of the model. LH provided PLICS data for the model and supervised the

70 data analysis. BS provided supervision throughout the model development and analysis. All authors
71 contributed to the drafting and finalisation of the manuscript.

72 **7. Acknowledgements**

73 Not applicable.

74

75 **Word count = 4,138** (excluding tables and references)

76 **Background**

77 The “two-week wait” (TWW) pathway for breast cancer, which stipulates that patients with suspected
78 cancer symptoms should be seen in secondary care within two weeks of their first GP presentation,
79 was first introduced in the UK in 1999 in response to the country’s poor breast cancer mortality
80 statistics (1). Based on concerns over the number of cancer cases continuing to be identified via
81 routine “symptomatic” referrals (i.e. where breast cancer is not initially suspected) (2), the TWW
82 pathway was subsequently extended to all patients with breast symptoms (i.e. not limited to
83 recognised cancer symptoms) (3). Similar TWW referral pathways are now in place for all major
84 cancers, with over two million TWW referrals occurring annually across England alone (4).

85 The last five years has seen a sharp rise in TWW referrals for breast cancer, from just under 542,000
86 across England in 2015/16, to over 612,000 in 2019/20 (a rise of almost 13%) (5, 6). Unsurprisingly,
87 breast cancer clinics are struggling to cope with the increased demand. Since 2018, the government’s
88 operational standard target – that 93% of patients should be seen within fourteen days of referral – has
89 not been achieved, and the ongoing COVID-19 pandemic has resulted in a further drop in recent
90 adherence to this target (6-9). At the same time, whilst regional variation in cancer prevalence rates
91 exists, less than 7% of patients referred along TWW cancer referral pathways are ultimately
92 diagnosed with cancer, suggesting that many of these referrals could be avoided (10). Strategies to
93 identify patients who do not require further investigation are urgently required to alleviate pressure on
94 breast cancer clinics.

95 In collaboration with the Leeds Teaching Hospitals NHS Trust (LTHT) and the University of Leeds,
96 PinPoint Data Science Ltd have developed a risk assessment tool, which is designed to determine
97 patients’ risk of breast cancer based on a number of routine blood tests (including haematological,
98 biochemical and tumour markers). These individual tests are combined within an algorithm
99 (henceforth referred to as the “PinPoint test”) to provide a calibrated risk probability of cancer (a
100 score between zero and one, with higher values indicating higher risk) (11). The PinPoint test can be
101 undertaken around the time of referral, providing utility for two main use-cases: (1) as a rule-out test
102 for patients with very low risk of cancer (i.e. avoiding secondary care referrals in this group); and (2)

103 as a tool to prioritise high risk patients (i.e. fast-tracking referrals for these patients). Thus far, early
104 diagnostic accuracy evidence suggests that for use-case (1) the test could avoid 20% of unnecessary
105 referrals, thus freeing up secondary care resources to focus on expedited diagnosis for those most at
106 risk (12).

107 Prior to commencement of the current study, initial discussions were undertaken with local
108 commissioners at Leeds (the Leeds Clinical Commissioning Group [CCG]), in order to determine
109 decision makers' primary requirements for adopting new interventions in this field. Based on that
110 work, the ability of new technologies to alleviate increasing pressure on secondary care services was
111 identified as a primary concern for clinical decision makers and commissioners. The aim of this early
112 exploratory evaluation was therefore to assess the potential impact of the PinPoint test on the flow of
113 patients through clinic services (focusing on use-case (1)), evaluating two primary outcomes: (i) the
114 percentage of patients seen in the clinic in under two weeks, and (ii) the number of 'overspill'
115 appointments generated (i.e. where patients have to return to the clinic for further diagnostics due to
116 insufficient same-day clinic capacity). Together these outcomes represent how well the referral
117 system achieves timely diagnoses for patients within an efficiently functioning system.

118 Discrete event simulation (DES) is a useful modelling technique which enables simulation of
119 individual entities (e.g. patients) through complex systems of activities (e.g. hospital services). With
120 the inclusion of activities dependent on constrained resources (e.g. staff, rooms, devices), the
121 possibility of queues forming in the system, leading to patient delays, can also be captured. Whilst
122 predominantly used in the context of manufacturing and engineering, the use of DES in healthcare has
123 been rising – with common applications including systems operation research, and disease
124 progression modelling (13, 14). In the context of breast cancer services, most DES applications to
125 date have focused on identifying optimal timings and/or technologies for breast cancer screening
126 programs, without consideration of capacity constraints (15-19). Notable exceptions include two
127 evaluations of mammography facilities – one in Brazil (20), the other USA (21) – which each
128 modelled the flow of patients through mammography services to determine optimal routine staffing
129 and equipment compositions. Similar methods are applied herein to instead explore the potential

130 utility of a new intervention, the PinPoint test, for improving patient workflow in secondary care
131 breast cancer clinics.

132 **Methods**

133 Our reporting of the study methods below adheres to good practice guidelines as outlined in the
134 Strengthening The Reporting of Empirical Simulation Studies (STRESS) checklist for DES models
135 (22). Please see **Additional File 4** for the completed STRESS-DES checklist.

136 ***Model Structure***

137 A DES model was constructed in Simul8 (<https://www.simul8.com>) to reflect the flow of patients
138 through the Leeds Teaching Hospitals Trust (LTHT) breast cancer clinic: a medium-to-large sized
139 clinic which sees around 10,500 patients along the TWW pathway annually. The model tracks
140 individual patients from their initial GP presentation, through to clinic services (including initial
141 assessment, mammogram, ultrasound and biopsy), accounting for available clinic resources (e.g. staff
142 and clinic rooms). Patients exit the model with a final diagnosis of breast cancer (following a multi-
143 disciplinary team [MDT] meeting) or no breast cancer.

144 In the standard care arm (see **Figure 1** for the model schematic), all patients receive a referral to the
145 clinic at their initial GP appointment; whilst in the PinPoint arm, referrals are based on whether
146 patients receive a low- or high-risk PinPoint test result (see **Figure 2** for an illustration of the
147 implementation pathway for the PinPoint test). Due to current uncertainty around the exact impact of
148 PinPoint testing on standard care (particularly around the management and behaviour of patients with
149 low-risk results), different scenarios are explored (see the *Analysis* section). Depending on the number
150 of patients already in the queue for the clinic, referred patients have to wait for a period of time for the
151 next available slot; similarly once in the clinic, patients must wait for the required staff and rooms to
152 be available in order to undergo their required investigations.

153 A warm-up period of twelve weeks is initially applied in the model to populate the service queues (i.e.
154 rather than starting with an empty system). The subsequent results collection period lasts one year,
155 and is intended to capture service demand levels matching those observed at the LTHT clinic in 2019.

156 **Model Parameters**

157 This section outlines the key model parameters – a full list is provided in **Additional files 1 and 2**.

158 The inter-arrival time of new patients into the model was set to an exponential distribution (mean =
 159 16.2778 minutes), which reflects the annual number of patients seen at the LTHT clinic (n=10,542;
 160 based on 2019 clinical audit data provided by the LTHT) assuming a steady arrival of patients. The
 161 prevalence of breast cancer was set to 4.76%, based on analysis of a bespoke data extract from the
 162 LTHT electronic health record and associated Leeds Patient Level Information and Costing System
 163 (PLICS) dataset for 2018/19.

164 Patients entering the clinic for the first time undergo an initial assessment. All patients with cancer
 165 were assumed to be referred for imaging, whilst 25% of patients without cancer were allowed to be
 166 discharged at this point (based on the LTHT audit data). The series of diagnostic activities undertaken
 167 for imaged patients was set based on the Leeds PLICs dataset: this data showed that, at the LTHT
 168 clinic, most patients without breast cancer undergo ultrasound only (39%), or some combination of
 169 mammogram and ultrasound (45%); whilst patients diagnosed with cancer most often undergo the full
 170 ‘triple assessment’ of mammogram, ultrasound and biopsy (85%) (see **Table 1**). Whilst a minority of
 171 patients with cancer were indicated as having *not* undergone biopsy in this dataset (30/362; 8.3%), it
 172 was assumed in the model that all patients with cancer *would* require a biopsy (based on clinical
 173 expert opinion), and this activity was therefore added to those patients’ sequence of events.

174 **Table 1. Proportion of patients following different sequences of breast cancer clinic diagnostic**
 175 **activities**

Sequence of clinic activities undertaken	Patients without breast cancer	Patients with breast cancer	Source
1) Mammogram only	Fixed proportions: 1) 0.012766 2) 0.272533 3) 0.035168 4) 0.394921 5) 0.181688 6) 0.023445 7) 0.060947 8) 0.017845 9) 0.000686	Fixed proportions: 1) 0.005525 2) 0.038122 3) 0.510497 4) 0.013812 5) 0.025414 6) 0.340331 7) 0.035912 8) 0.027624 9) 0.002762	LTHT electronic health record and Leeds PLICs data extract for 2018/19. Data included N=362 patients diagnosed with breast cancer vs. N=7,285 patients not diagnosed with breast cancer ^b .
2) Mammogram and ultrasound ^a			
3) Mammogram, Ultrasound and biopsy ^a			
4) Ultrasound only			
5) Ultrasound and mammogram ^a			
6) Ultrasound, mammogram and biopsy ^a			
7) Ultrasound and biopsy			
8) Biopsy only			
9) Mammogram and biopsy			

^aFor pathways involving mammogram and ultrasound, the proportion undergoing mammogram first was set to 60%, vs. 40% for ultrasound first in the model, based on expert clinical opinion.
^bCases listed under the heading 'other' in this data extract [N=125 in total] were excluded from this analysis.
PLICS = Patient Level Information and Costing System

176

177 In line with the LTHT clinic schedule, the model includes seven weekly 'full' clinics (Mon AM, Tues
178 PM, Weds AM & PM, Thurs AM & PM, and Fri AM), and one weekly 'add-on' clinic with a reduced
179 capacity (Tues AM; this clinic was first introduced in early 2018 as a temporary measure to alleviate
180 pressure on the clinic, but has since been permanently adopted due to persisting demand). All clinics
181 last four hours (AM = 09:00 to 13:00; PM = 14:00 to 18:00), with up to fifteen minutes of staff
182 overtime allowed to complete activities if necessary. The clinic staff includes radiological and
183 surgical staff (consultants, nurse practitioners [NPs] and physician associates [PAs]); and
184 radiographer staff (Band 6 sonographers and non-sonographers, Band 7 sonographers and Grade 2
185 assistants). Staff numbers were set to match the LTHT staff schedule, and staff availability within
186 shifts was set based on expert opinion as to the amount of time each staff member would typically
187 spend on 'other' activities (e.g. administrative tasks and follow-up appointments) (see **Additional**
188 **files 1 and 2**). Patients are not assigned to a specific member of staff – rather, as soon as any relevant
189 staff member becomes available for the patient's next required activity, the patient can undergo that
190 activity.

191 Based on consultation with LTHT clinic staff, the default number of new patients booked into each
192 clinic was set to twenty-five for full clinics, and ten for the Tues AM add-on clinic. Whilst these are
193 the 'target' clinic numbers, the clinic audit data indicated that the full clinic numbers could fluctuate
194 (little variation was observed in the Tues AM clinic). It was confirmed that full clinic numbers would
195 be increased in response to periods of higher demand, in an attempt to meet the TWW target. In the
196 model therefore, above a clinic queue of 380 (i.e. slightly above the number that can be seen over two
197 weeks at the default clinic numbers), the number of new patients booked into the next full clinic was
198 allowed to increase by 1 for every additional 15 patients in the queue, up to a maximum of 34. The
199 clinic numbers thus reflect a degree of 'responsiveness' to the queue, in line with real-life practice.
200 This approach was able to produce similar proportions of patients meeting the TWW target in the

201 model standard care arm (66.3%), as seen in NHS referral data for the Leeds CCG in 2019 (66.5%)
202 (23). All queues in the system were set to operate on a ‘first in first out’ basis – such that those
203 patients waiting the longest in queues are always the first to be selected for the associated activity.

204 Clinics may close with patients still waiting in the activity queues. In this case, the ‘overspill’ patients
205 are routed out of the clinic and placed in a queue to return to the clinic at a later date. Based on the
206 audit data, five appointments are typically reserved per LTHT full clinic to see overspill patients from
207 previous clinics, with a slightly higher number (six) observed for the Tues AM clinic. The model
208 therefore allows up to five and six overspill patients to be seen per full clinic and Tues AM clinic
209 respectively (in addition to new patients).

210 The maximum number of each clinic activity able to be undertaken at any given time was based on
211 the number of rooms (each with one available imaging device) available at the LTHT clinic (four
212 initial assessment; three mammogram; four ultrasound; and four biopsies). The actual number of each
213 activity undertaken at any point depends also on the availability of staff: an activity can only go ahead
214 if both a room and required staff are available. The median times taken to complete each activity was
215 based on expert opinion (initial assessment = 10 minutes; mammogram = 20 minutes; ultrasound = 20
216 minutes; biopsy = 30 or 45 minutes [each with 50% chance of occurring]), allowing for some
217 variation around the expected timings (see **Additional File 1**).

218 The sensitivity (0.98) and specificity (0.20) values applied for the Pinpoint test were provided by the
219 manufacturer, based on an unpublished test development and validation study. This study included
220 data on a total of n=14,021 patients referred along the TWW pathway for breast cancer at LTHT,
221 between 2011-16 [study development set] and 2017-19 [study validation set]). Full details of this
222 study are now available in a published manuscript (12). Other key parameters for the Pinpoint arm
223 were altered within scenario and secondary analyses, as outlined further below.

224 ***Validation***

225 Face validity of the model was checked via a series of consultations with clinicians at the LTHT
226 clinic. Internal validity of the model code was confirmed using extreme value tests, and using the

227 Simul8 inbuilt ‘Simulation Monitor’ function. Finally, external validity of the model was determined
228 by comparing primary baseline results from the model against real world data: (i) the simulated
229 proportion of patients meeting the TWW target (66.3%) were compared against NHS England data for
230 the same time period (66.5%) (23); and the number of simulated overspill appointments (N=1,685)
231 were compared against the annual value reported in the LTHT audit data (N=1,664).

232 *Analysis*

233 All results are based on 150 model trials (i.e. running the model 150 times, using different random
234 number sequences), and using deterministic analysis (i.e. probabilistic sensitivity analysis was not
235 conducted due to the early nature of this analysis). The number of trials and warm-up period were set
236 to a level sufficient to produce stable model outputs (ascertained by visual inspection of plotted model
237 outputs).

238 For Pinpoint, due to current uncertainty as to the exact impact of the test on standard care, two
239 primary scenarios were explored:

- 240 • **Scenario 1:** GPs only refer patients with high-risk results (i.e. 100% adherence to testing), and
241 all patients with cancer who receive a low-risk test result are assumed to return after 6 weeks
242 with persisting symptoms and receive a delayed clinic referral.
- 243 • **Scenario 2:** GPs overrule 20% of low-risk results (cancerous and non-cancerous cases), and a
244 further 10% of patients without breast cancer with a low-risk test result are also assumed to
245 return and receive a delayed referral at six weeks.

246 In addition to the above, based on the premise that Pinpoint could significantly reduce referrals and
247 free up clinic capacity, the following service reconfiguration scenarios were explored: (1) removing
248 the Tues AM add-on clinic; (2) removing a full clinic (arbitrarily chosen as Wed AM); and (3)
249 removing the Tues AM and Wed AM clinics. These options were applied together with the Pinpoint
250 Scenario 2 parameters. A range of secondary analyses were also conducted to explore the impact of
251 altering the levels of GP adherence, delayed referrals, diagnostic accuracy, cancer prevalence and
252 patient arrivals (see **Additional File 3**).

253

254 **Results**

255 ***Referral patterns***

256 Based on average simulated patient numbers over 150 model runs, under standard care, 100%
257 (n=10,528) of patients receive an immediate referral. With Pinpoint, 81% (n=8,544/ 10,550) of
258 patients completing the model were referred under Scenario 1: this included all patients with breast
259 cancer (n=505), 2% (n=10) of whom received a delayed (rather than immediate) referral; and 80%
260 (n=8,039/10,044) of patients without cancer (all referred immediately). Under Scenario 2, 86%
261 (n=9,107/10,550) of patients received a referral: all patients with breast cancer (n=505), 2% (n=8) of
262 whom received a delayed referral; and 86% (n=8,602/ 10,044) of patients without breast cancer, 2%
263 (n=161) of whom also received a delayed referral. Note that in both scenarios, the average number of
264 patients completing the model in the PinPoint arm is higher than in the standard care arm, due to the
265 fact that more patients remain in the system queues (i.e. the TWW referral queue, and the overspill
266 Clinic Returns queue) at the end of the simulation in the standard care arm compared to the PinPoint
267 arm.

268 ***Primary outcomes***

269 **Table 2** shows that the reduction in referrals achieved with the PinPoint test is expected to shorten the
270 time to clinic for those referred, by three to four days on average. Consequently the percentage of
271 patients seen in the clinic in under two weeks is increased, from around 66% with standard care, to
272 between 100 (Scenario 1) and 98% (Scenario 2) with the Pinpoint test. Overspill cases are also
273 reduced – from an average of 1,685 with standard care (a number which closely matches the number
274 of overspill appointments recorded in the LTHT 2019 audit data i.e. n=1,664), to between 727
275 (Scenario 1) or 886 (Scenario 2) with Pinpoint.

276 **Table 2** further illustrates that, applying the Scenario 2 parameters, the reduction in referrals achieved
277 with the Pinpoint test is sufficient to allow the Tues AM add-on clinic to be removed from the weekly
278 clinic schedule: this option maintains the percentage meeting the TWW target at close to 95%, and

279 keeps the overspill cases (n= 1,292) well below that seen with standard care (albeit higher than the
280 PinPoint main scenario analyses). Any further reductions to the schedule are not tolerated however,
281 with the removal of the full Wed AM clinic resulting in less than 3% of patients meeting the TWW
282 requirement and high overspill numbers (n = 1,632).

283 **Table 2. Model results: primary outcomes for standard care, PinPoint testing scenarios and service reconfiguration scenarios**

Strategy	Number completing the model (95% CI)			Average time to clinic [week days] (95% CI)		Percentage achieving TWW Target (95% CI)			Number of Overspill (95% CI)
	Total	BC	No BC	BC	No BC	BC	No BC	Total	
Standard care	10,528 (10,511 to 10,545)	503 (499 to 507)	10,025 (10,008 to 10,042)	9.81 (9.81 to 9.82)	9.81 (9.81 to 9.81)	66.4% (66.0 to 66.9)	66.3% (66.0 to 66.5)	66.3% (66.0 to 66.5)	1,685 (1,648 to 1,722)
Pinpoint scenarios									
Scenario 1 [0% GP override; 0% true negatives receive delayed referral]	10,549 (10,532 to 10,567)	505 (502 to 509)	10,044 (10,027 to 10,061)	6.23 (6.20 to 6.25)	5.64 (5.63 to 5.64)	98.0% (97.9 to 98.1)	100% (100 to 100)	99.9% (99.9 to 99.9)	727 (707 to 746)
Scenario 2 [20% GP override; 10% true negatives receive delayed referral]	10,550 (10,532 to 10,567)	505 (502 to 509)	10,044 (10,027 to 10,061)	6.28 (6.25 to 6.31)	6.36 (6.35 to 6.38)	98.4% (98.3 to 98.5)	98.1% (98.1 to 98.1)	98.1% (98.1 to 98.2)	886 (861 to 911)
Service reconfiguration scenarios (applied with Pinpoint Scenario 2 parameters)									
No Tues AM clinic [capacity = 10 new patients + 6 over spills]	10,497 (10,484 to 10,510)	502 (499 to 506)	9,995 (9,982 to 10,008)	7.75 (7.61 to 7.89)	7.83 (7.69 to 7.97)	95.0% (93.8 to 96.2)	94.8% (93.7 to 96.0)	94.8% (93.7 to 96.0)	1,292 (1260 to 1324)
No Weds AM clinic [capacity = 25 to 34 new patients + 5 over spills]	10,470 (10,453 to 10,487)	498 (495 to 502)	9,972 (9,954 to 9,989)	11.72 (11.69 to 11.75)	11.81 (11.79 to 11.82)	2.9% (2.3 to 3.4)	2.9% (2.3 to 3.4)	2.9% (2.3 to 3.4)	1,632 (1,596 to 1,668)
No Tues AM or Weds AM clinic	10,274 (10,275 to 10,291)	461 (459 to 464)	9,813 (9,796 to 9,830)	12.49 (12.46 to 12.52)	12.58 (12.57 to 12.58)	0.0% (0.0 to 0.0)	0.0% (0.0 to 0.0)	0.0% (0.0 to 0.0)	2,057 (2,042 to 2,071)

BC = breast cancer; CI = confidence interval.

284 The results were robust to the secondary analyses explored (see **Additional file 3**). The incremental
285 benefits associated with the PinPoint test were slightly reduced when (a) increasing the proportion of
286 GP overrides up to 50%, or (b) increasing the proportion of non-cancerous patients receiving a
287 delayed referral up to 50%; however the test maintained significantly higher TWW percentage values
288 and lower overspill numbers compared to standard care, across all of the secondary analyses
289 conducted. The test-based strategy was also more robust than standard care at coping with increased
290 patient numbers: for example, when increasing the number of patients arriving in the model by 10%,
291 the PinPoint test was able to maintain 99.9% of patients meeting the TWW target, with an average of
292 1,156 overspills; whilst the same scenario for standard care led to a drop in the overall percentage
293 meeting the TWW target (to 61.2%), with an average of 2,555 overspills.

294 Discussion

295 Based on early diagnostic accuracy data and clinical assumptions, the PinPoint test could provide
296 significant relief to breast cancer clinics, enabling the majority of referred patients to be seen within
297 two weeks and allowing more patients to receive their full sequence of diagnostic assessments in a
298 single clinic visit. It is further possible that this reduction in clinic demand could be sufficient to
299 remove the LTHT weekly add-on clinic, if the benefits of doing so (e.g. staff relief, cost savings,
300 shifting resources) could be considered to outweigh the associated costs (e.g. slightly lower
301 percentage of patients meeting the TWW target, and higher overspill numbers). It is of particular
302 interest to note that, whilst in simple terms the test is expected to remove 20% of patients from the
303 TWW pathway (based on its 20% specificity), this does not translate to being able to remove 20% of
304 the clinic schedule (i.e. one full clinic). This is because of the significant extra demand in workload
305 the department is already attempting to meet by regularly expanding their clinics to maximum
306 capacity; removing some of that excess demand means that clinics are more able to regularly run at
307 their intended (rather than maximum) capacity.

308 As with any early model-based analysis, this assessment has limitations. First, the model is based on
309 data from a single centre, and the results are therefore only expected to reflect the impact of the test
310 on similar medium-to-large sized clinics across the UK. The applicability of the findings to other

311 NHS clinics, particularly those of a different size or alternative configurations to the Leeds clinic, is
312 unclear. Second, due to the early nature of this assessment, several of the model parameters were set
313 based on expert opinion. Ideally a site visit to observe the actual flow of patients through the LTHT
314 clinic would have been undertaken, but was not possible due to the ongoing COVID pandemic.
315 Nevertheless, the availability of clinic audit data and the bespoke NHS PLICs dataset for Leeds
316 allowed most parameters to be set or validated against real world data. Most importantly for the
317 PinPoint arm, key assumptions had to be made around the management and behaviour of patients with
318 low-risk results, for which there is currently no available evidence. If and when further information on
319 these parameters becomes available, the model can be easily updated to provide a more precise
320 evaluation.

321 Additional uncertainty around the applicability of these findings stems from the ongoing fallout of the
322 COVID-19 pandemic, which has had a major impact on cancer referral patterns (24, 25). At the time
323 of analysis planning (mid 2020), the demand for breast cancer clinic services at the LTHT was
324 considered to be unpredictable due to the impact of successive national and regional “lock-downs”.
325 Nevertheless, based on expert consultation, only a slight drop in patient numbers was observed over
326 the initial national lock-down period (early 2020), with numbers expected to quickly return to pre-
327 pandemic levels following continued easing of restrictions. The decision was therefore made to base
328 the analysis on pre-pandemic data from 2019. Going forward, it is expected that referrals will likely
329 rise above pre-pandemic levels. If that expectation holds true, based on our early analysis the PinPoint
330 test would potentially be better enable secondary care breast cancer services to cope with such
331 increases in demand, and could therefore be of increased utility.

332 Whilst the findings of this exploratory study are encouraging, additional outcomes – most importantly
333 patient health outcomes and health-economic outcomes – would require evaluation before adoption of
334 the PinPoint test could be definitively recommended. Of particular concern is the clinical management
335 and outcomes for those 20% of patients initially ruled-out by the PinPoint test. This group was
336 explored in the current model via sensitivity analyses, which show how the model outcomes may
337 change if a higher proportion of initially discharged patients return to their GP for a later referral.

338 However, the potential impact on health outcomes for this group were not explored. Although this
339 group consists predominantly of patients without cancer, the significant risks associated with delayed
340 or missed diagnoses for those few patients with cancer is such that some form of safety-netting
341 guidance is expected to be required, in order to instil confidence that patient harm may be avoided.
342 Repeated testing and/or a follow-up GP visit could be implemented in this group, for example, as a
343 means of protection both for those patients with cancer, and for those patients without cancer who
344 may experience persisting symptoms resulting from other indications requiring further follow-up.
345 Clearly the implementation of any such safety-netting procedures would have an impact on both
346 healthcare costs and patient health outcomes. An early economic evaluation is currently underway to
347 explore the impact of different implementation scenarios core to the health-economic argument for the
348 use of the PinPoint test, compared to current practice. The findings of that analysis will help to
349 determine whether further primary research is required in order to address these aspects of
350 uncertainty.

351 The results of this early-stage evaluation were used to help secure further funding for a service
352 evaluation of the PinPoint test across multiple sites in Yorkshire (26). That project will aim to
353 determine the real-world performance of the test; establish the logistics of implementing the test in the
354 NHS; and update the early evaluation described herein, to address key uncertainties highlighted in the
355 analysis and incorporate cost and health outcomes data. The results of the service evaluation will be
356 reported to NHS England.

357 On a final note, alternative strategies have been suggested for reducing the burden on secondary care
358 services. Blacker and colleagues (27), for example, suggest that separate non-urgent clinics for breast
359 pain and breast lumps in patients aged under thirty could be set up, based on the low incidence of
360 cancer in this group. Ramzi and colleagues (28) have further demonstrated that using age as a single
361 referral criterion provides higher diagnostic accuracy than the TWW pathway, and would be expected
362 to be less costly. Other multi-variate prediction models, which avoid the need for any additional
363 laboratory-based tests, have also been suggested (29). The use of the PinPoint test as a prioritisation
364 test for referrals (i.e. use-case (2)), in addition to its role as a rule-out test, also deserves further

365 exploration(12). Ideally future studies should consider the comparative utility of alternative rule-out
366 and/or priority-setting referral strategies, so that the most clinically- and cost-effective option may be
367 selected.

368

369 **Conclusions**

370 Based on early data, this exploratory analysis found that the PinPoint risk assessment test could help
371 to alleviate pressure on cancer clinics. Further research is now required to assess broader clinical and
372 economic impacts, and to determine outcomes and risks for those patients deemed to be low-risk on
373 the PinPoint test.

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391 **Figure captions**

392 **Figure 1. Model figure for the standard care (no primary care testing) pathway (GP = general**
393 **practitioner; TWW = two week wait; MDT = multi-disciplinary team)**

394 **Figure 1 Legend:** Patients with suspected breast cancer enter the model at the GP arrivals point.
395 Individual patients are then tracked through the model. The yellow box captures the activities of the
396 breast cancer clinic (i.e. initial assessment; mammogram; ultrasound and biopsy), which each depend
397 the availability of rooms and staff. Patients are required to wait in the activity queues until such a time
398 as an available room and required staff members are available. At the end of each scheduled clinic,
399 any patients left in the clinic activity queues are routed back around to the ‘Clinic returns’ activity and
400 will be required to attend a future clinic to finish their course of diagnostics. Once an individual’s
401 clinic activities have been completed, the patient receives a diagnosis of cancer or no cancer, and exits
402 the model at the associated exit point.

403

404 **Figure 2. Expected implementation pathway for the PinPoint test (GP = general practitioner;**
405 **TWW = two week wait).**

406

407 **List of abbreviations**

408 BC = breast cancer

409 CCG = Clinical Commissioning Group

410 CI = confidence interval

411 DES = discrete event simulation

412 LTHT = Leeds Teaching Hospitals Trust

413 GP = General practitioner

414 MDT = multi-disciplinary team

415 NP = nurse practitioner

416 PA = physician associate

417 PLICS = Patient Level Information and Costing System


418 TWW = two-week wait

419 UK = United Kingdom

420 References

- 421 1. Potter S, Govindarajulu S, Shere M, Braddon F, Curran G, Greenwood R, et al. Referral
422 patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast
423 cancer: prospective cohort study. *BMJ*. 2007;335(7614):288.
- 424 2. Sauven P. Impact of the '2 week wait' on referrals to breast units in the UK. *The Breast*.
425 2002;11(3):262-4.
- 426 3. National Collaborating Centre for Cancer. Suspected cancer: recognition and referral. NICE
427 Guideline [NG12]. <https://www.nice.org.uk/guidance/ng12>. Accessed April 2021.
- 428 4. NHS England. Annual NHS cancer checks top two million for the first time.
429 <https://www.england.nhs.uk/2019/04/annual-nhs-cancer-checks-top-two-million-for-the-first-time/>.
430 Accessed April 2021.
- 431 5. NHS England. Cancer Waiting Times Annual Report, 2015-16.
432 [https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cwt-annual-report-2015-16/)
433 [reports/cwt-annual-report-2015-16/](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cwt-annual-report-2015-16/). Accessed April 2021.
- 434 6. NHS England. Cancer Waiting Times Annual Report, 2019-20.
435 [https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cancer-waiting-times-annual-report-2019-20/)
436 [reports/cancer-waiting-times-annual-report-2019-20/](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cancer-waiting-times-annual-report-2019-20/). Accessed April 2021.
- 437 7. NHS England. Cancer Waiting Times Annual Report, 2017-18.
438 [https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cancer-waiting-times-annual-report-2017-18/)
439 [reports/cancer-waiting-times-annual-report-2017-18/](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/cancer-waiting-times-annual-report-2017-18/). Accessed April 2021.
- 440 8. NHS England. Cancer Waiting Times Annual Report, 2018-19.
441 [https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-cancer-waiting-times-annual-report-2018-19/)
442 [reports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-cancer-waiting-times-](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-cancer-waiting-times-annual-report-2018-19/)
443 [annual-report-2018-19/](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-reports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-cancer-waiting-times-annual-report-2018-19/). Accessed April 2021.
- 444 9. Nuffield Trust & The Health Foundation. Cancer waiting times.
445 <https://www.nuffieldtrust.org.uk/resource/cancer-waiting-time-targets#background>. Accessed April
446 2021.
- 447 10. NHS England. Cancer Waiting Time Statistics.
448 <http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times>. Accessed April
449 2021.
- 450 11. PinPoint Data Science Ltd. Early Cancer Detection. <https://www.pinpointdatascience.com/>.
451 Accessed April 2021.
- 452 12. Savage R, Messenger M, Neal RD, Ferguson R, Johnston C, Lloyd KL, et al. Development and
453 validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic
454 patients referred urgently from primary care: a diagnostic accuracy study. *BMJ Open*.
455 2022;12(4):e053590.
- 456 13. Zhang X. Application of discrete event simulation in health care: a systematic review. *BMC*
457 *health services research*. 2018;18(1):1-11.
- 458 14. Vázquez-Serrano JI, Peimbert-García RE, Cárdenas-Barrón LE. Discrete-Event Simulation
459 Modeling in Healthcare: A Comprehensive Review. *International journal of environmental research*
460 *and public health*. 2021;18(22):12262.
- 461 15. Bessen T, Keefe DM, Karnon J. Does one size fit all? Cost utility analyses of alternative
462 mammographic follow-up schedules, by risk of recurrence. *International Journal of Technology*
463 *Assessment in Health Care*. 2015;31(5):281-8.
- 464 16. Comas M, Arrospe A, Mar J, Sala M, Vilapinyó E, Hernández C, et al. Budget impact
465 analysis of switching to digital mammography in a population-based breast cancer screening
466 program: a discrete event simulation model. *PLoS One*. 2014;9(5):e97459.
- 467 17. Furzer J, Tessier L, Hodgson D, Cotton C, Nathan PC, Gupta S, et al. Cost-Utility of Early
468 Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin
469 Lymphoma. *J Natl Cancer Inst*. 2020;112(1):63-70.

- 470 18. Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, et al. Comparative
471 effectiveness of combined digital mammography and tomosynthesis screening for women with
472 dense breasts. *Radiology*. 2015;274(3):772-80.
- 473 19. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG.
474 Retrospective Cost-effectiveness Analysis of Screening Mammography. *JNCI: Journal of the National
475 Cancer Institute*. 2006;98(11):774-82.
- 476 20. Coelli FC, Ferreira RB, Almeida RMV, Pereira WCA. Computer simulation and discrete-event
477 models in the analysis of a mammography clinic patient flow. *Computer methods and programs in
478 biomedicine*. 2007;87(3):201-7.
- 479 21. Amir T, Lee B, Woods RW, Mullen LA, Harvey SC. A pilot of data-driven modeling to assess
480 potential for improved efficiency in an academic breast-imaging center. *Journal of Digital Imaging*.
481 2019;32(2):221-7.
- 482 22. Monks T, Currie CS, Onggo BS, Robinson S, Kunc M, Taylor SJ. Strengthening the reporting of
483 empirical simulation studies: Introducing the STRESS guidelines. *Journal of Simulation*.
484 2019;13(1):55-67.
- 485 23. NHS England. 2018/19 Monthly Provider Cancer Waiting Times Statistics.
486 [https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-prov-
487 cwt/2018-19-monthly-provider-cancer-waiting-times-statistics/](https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-prov-cwt/2018-19-monthly-provider-cancer-waiting-times-statistics/). Accessed April 2021.
- 488 24. Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and impact on breast
489 cancer diagnoses: what happened in England in the first half of 2020. *British Journal of Cancer*.
490 2021;124(4):710-2.
- 491 25. Dave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, et al. Breast cancer
492 management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase
493 of the B-MaP-C study. *British Journal of Cancer*. 2021:1-10.
- 494 26. West Yorkshire and Harrogate Cancer Alliance. The PinPoint Test
495 <https://canceralliance.wyhpартnership.co.uk/our-work/innovations-programme/pinpoint-test>.
496 Accessed May 2022.
- 497 27. Blacker S, Jordache R, Pakzad F. P029: Can two week wait breast cancer referrals be triaged
498 to prioritise high risk patients for early diagnosis and treatment? *European Journal of Surgical
499 Oncology*. 2020;46(6):e18.
- 500 28. Ramzi S, Cant P. Comparison of the urgent referral for suspected breast cancer process with
501 patient age and a predictive multivariable model. *BJS open*. 2021;5(2):zraa023.
- 502 29. Galvin R, Joyce D, Downey E, Boland F, Fahey T, Hill AK. Development and validation of a
503 clinical prediction rule to identify suspected breast cancer: a prospective cohort study. *BMC cancer*.
504 2014;14(1):1-8.
- 505




Patient presents to GP with symptoms suggestive of cancer

PinPoint Test ordered: bloods taken



PinPoint processes data



(within NHS firewall)

Results returned within 48 hours: Probability of patient having cancer



High/ Intermediate risk

Patient continues through TWW pathway as normal

Low risk

Patient not referred through TWW pathway; possible non-cancer pathway options